Boundless Bio, Inc. Common Stock (BOLD)vsInsmed Inc (INSM)
BOLD
Boundless Bio, Inc. Common Stock
$1.13
-1.74%
HEALTHCARE · Cap: $26.66M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
BOLD leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
BOLD
Avoid30
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BOLD
The strongest argument for BOLD centers on Price/Book.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : BOLD
The primary concerns for BOLD are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
BOLD profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM is growing revenue faster at 1.5% — sustainability is the question.
BOLD generates stronger free cash flow (-11M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boundless Bio, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Audentes Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious and life-threatening rare diseases caused by single gene defects. The company is headquartered in San Francisco, California.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?